is ketamine a bronchodilator
Yes, ketamine is a bronchodilator. It works primarily by stimulating catecholamine release (sympathomimetic effect), which causes bronchial smooth muscle relaxation. It also has some direct relaxant effects on bronchial smooth muscle. This makes it useful for RSI in asthmatic or bronchospastic patients.
Searching sources...
Reading File
Searching the Web
ketamine bronchodilator mechanism bronchospasm
Finding Sources
Yes, ketamine is a bronchodilator. Here is a full breakdown from authoritative textbooks and current evidence:
Ketamine as a Bronchodilator
Mechanism of Action
Ketamine causes bronchodilation through several mechanisms:
- Sympathomimetic / catecholamine release - the primary mechanism. Ketamine inhibits catecholamine reuptake and stimulates release, leading to beta-2 adrenergic receptor activation and bronchial smooth muscle relaxation.
- Direct smooth muscle relaxation - ketamine relaxes bronchial smooth muscle independent of its adrenergic effects (Tintinalli's EM).
- Voltage-sensitive calcium channel blockade - interrupts calcium influx into smooth muscle cells.
- Muscarinic/nicotinic receptor inhibition - blocks postsynaptic muscarinic and nicotinic receptors.
- Nitric oxide downregulation - reduces inducible nitric oxide synthase (iNOS) activity, lowering NO levels that contribute to bronchospasm.
- Anti-inflammatory effects - interrupts the inflammatory cascade that drives airway hyperreactivity.
Notably, the NMDA receptor (ketamine's classic target) does NOT appear to be the main driver of its bronchodilatory effect - research by Sato et al. (1998) showed NMDA agonists failed to block ketamine-induced smooth muscle relaxation.
Stereoisomers: Racemic vs. S(+)
An important nuance from Morgan & Mikhail (7e):
"Racemic ketamine is a potent bronchodilator... however, S(+) ketamine produces minimal bronchodilation."
This means the commonly used S-ketamine (esketamine) used in Europe may have less bronchodilatory benefit than the racemic mixture used in the US.
Clinical Applications
| Setting | Role |
|---|---|
| Asthmatic patients requiring RSI | Drug of choice for induction - sympathomimetic + bronchodilatory effects |
| Status asthmaticus | Secondary/adjunct agent when beta-2 agonists, anticholinergics, corticosteroids, and IV magnesium fail |
| Hemodynamically unstable asthmatic | Ideal - provides both cardiovascular support and bronchodilation |
| Mechanically ventilated asthmatics | Reduces airway resistance and improves pulmonary compliance |
Important Caveats
- Not a sole bronchodilator - Barash (9e) notes it is "not effective as a sole agent for the treatment of bronchospasm" and should be a secondary agent.
- Rosen's EM notes that while studies suggest possible benefit in acute asthma, no statistically significant findings have been confirmed, and "ketamine is not recommended for acute [asthma]" as a primary treatment outside of RSI.
- Increases salivation (consider pre-treatment with an antisialogogue like glycopyrrolate).
- Preserves airway reflexes and spontaneous ventilation - an advantage over other induction agents.
Dosing for Bronchospasm (from literature)
- Bolus: 0.1-2 mg/kg IV
- Continuous infusion: 0.15-2.5 mg/kg/hr
- Nebulized ketamine has also been studied in status asthmaticus
Bottom line: Yes, ketamine is a clinically meaningful bronchodilator - it's the preferred induction agent in asthmatic patients and a recognized adjunct in refractory status asthmaticus, with the Frontiers in Pediatrics case report and a comprehensive review in PMC supporting its use in bronchospasm unresponsive to conventional treatment.
This is a shared conversation. Sign in to Orris to start your own chat.